Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 16/20 | 0.56 |
| ▸ | KCNJ3 | P48549 | 16/20 | 0.56 |
| ▸ | KCNJ5 | P48544 | 12/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247313 | 0.99 | KCNJ6 (0.56) | KCNJ6KCNJ3KCNJ5KDRMET | |
| SCHEMBL2243375 | 0.93 | KCNJ6 (0.55) | KCNJ6KCNJ3KCNJ5KDRBRAF | |
| SCHEMBL2247780 | 0.91 | KCNJ6 (0.55) | KCNJ6KCNJ3KCNJ5KDRBRAF | |
| SCHEMBL2245642 | 0.90 | KCNJ6 (0.60) | KCNJ6KCNJ3KCNJ5KDRBRAF | |
| SCHEMBL2242919 | 0.88 | KCNJ6 (0.55) | KCNJ6KCNJ3KCNJ5KDRMET | |
| SCHEMBL2243743 | 0.88 | KCNJ6 (0.58) | KCNJ6KCNJ3KCNJ5KDRBRAF | |
| SCHEMBL2247616 | 0.87 | MAPK14 (0.54) | KCNJ6KCNJ3KCNJ5KDRMET | |
| SCHEMBL2243256 | 0.86 | KCNJ6 (0.54) | KCNJ6KCNJ3KCNJ5KDRMET | |
| SCHEMBL2241060 | 0.85 | MAPK14 (0.54) | KCNJ6KCNJ3KCNJ5KDRMET | |
| SCHEMBL2243159 | 0.85 | BRAF (0.58) | KDRMETBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | claimed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | KCNJ6 4292/4885KCNJ3 4108/4885KCNJ5 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.